From this, in the present study, we investigated whether a component of ECM namely COMP, which has been demonstrated to be significantly increased in the circulation of BA patients, especially those with fibrosis, may have a potential as a non-invasive biomarker of liver fibrosis. This evidence concerns the gene COMP and Hepatic fibrosis.